Ensysce Biosciences, Inc. (ENSC) Financials
Annual revenue, profitability and per-share results for Ensysce Biosciences, Inc., as reported in SEC filings.
Revenue • FY2025
$5.07M
▼ 2.8%YoY
Net income • FY2025
-$10.18M
▼ 27.4%YoY
Diluted EPS • FY2025
-$3.98
▲ 65.2%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $5.07M | -$10.18M | — | -$3.98 | -$7.93M | -202.1% | -2.8% |
| FY2024 | $5.21M | -$7.99M | — | -$11.45 | — | -129.2% | +133.6% |
| FY2023 | $2.23M | -$10.61M | — | -$4.69 | — | -480.5% | -11.6% |
| FY2022 | $2.52M | -$24.17M | — | — | — | -959.9% | -28.5% |
Figures as reported in Ensysce Biosciences, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a ENSC filing.
Get an email when ENSC files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.